New Shingles Vaccine
We now carry the newest Shingles vaccine, SHINGRIX. This vaccine in indicated for the prevention of Herpes Zoster (shingles) in adults aged 50 years and older. SHINGRIX demonstrated efficacy against shingles by 90% across all age groups, as well as sustained efficacy over a follow-up period of 4 years. By preventing shingles, SHINGRIX also reduced the overall incidence of postherpetic neuralgia (PHN), a form of chronic nerve pain associated with shingles. PHN is the most common complication of the shingles virus, which involves pain lasts at least three months up to several years after the rash has cleared.
SHINGRIX is administered in two doses between 2 and 6 months apart. This vaccine is not recommended for those with suppressed immune systems or those who are allergic to any of its ingredients, or those who have had an allergic reaction to a previous dose of SHINGRIX. SHINGRIX is not indicated for the prevention of Chickenpox.
The previous vaccine ZOSTAVAX, although effective, has been shown to prevent the shingles vaccine by up to 50% and is more efficacious in younger age groups. However, ZOSTAVAX is effective in reducing the severity of the shingles virus.